TABLE 4.
Treatment strategies for IE due to non-HACEK GNB
| Antibiotic therapya | No. (% of totalb) |
|---|---|
| Noncarbapenem β-lactamc ± aminoglycosides ± fluoroquinolones | 29 (50) |
| Penicillin or cephalosporin only | 5 |
| Non-carbapenem β-lactam + aminoglycosides | 14 |
| Non-carbapenem β-lactam + fluoroquinolones | 8 |
| Non-carbapenem β-lactam + aminoglycosides + fluoroquinolones | 2 |
| Carbapenem ± aminoglycosides ± fluoroquinolones | 8 (13.8) |
| Carbapenem only | 3 |
| Carbapenem + aminoglycosides | 1 |
| Carbapenem + fluoroquinolones | 3 |
| Carbapenem + aminoglycosides + fluoroquinolones | 1 |
| Noncarbapenem β-lactam +carbapenem ± aminoglycosides ± fluoroquinolones | 13 (22.4) |
| Non-carbapenem β-lactam + carbapenem | 4 |
| Non-carbapenem β-lactam + carbapenem + aminoglycosides | 3 |
| Non-carbapenem β-lactam + carbapenem + fluoroquinolones | 4 |
| Non-carbapenem β-lactam + carbapenem + aminoglycosides + fluoroquinolones | 2 |
| Colistin-containing regimens | 3 (5.2) |
| Colistin + carbapenem + rifampin | 2 |
| Colistin + penicillin or cephalosporin + carbapenem + rifampin | 1 |
| Other regimens | 5 (8.6) |
| Non-carbapenem β-lactam + rifampin | 1 |
| Non-carbapenem β-lactam + tobramycin + clindamycin | 1 |
| Aminoglycosides + rifampin | 1 |
| Aminoglycosides + fluoroquinolones + rifampin | 2 |
a
±, with or without.
b
A total of 58 patients with IE due to non-HACEK GNB were studied.
c
Includes penicillin alone, penicillin–penicillinase inhibitor combinations, and third-generation cephalosporins.